Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Carcinoma, Non-Small-Cell Lung 193Lung Neoplasms 80Pancreatic Neoplasms 47Neoplasms 31Non-Squamous Non-Small Cell Lung Cancer 19Head and Neck Neoplasms 19Glioblastoma 19Adenocarcinoma of Lung 19Squamous Cell Carcinoma of Head and Neck 18Neoplasm Metastasis 17Gliosarcoma 17Brain Neoplasms 17Breast Neoplasms 16Rectal Neoplasms 13Colorectal Neoplasms 13Colonic Neoplasms 13Adenocarcinoma, Bronchiolo-Alveolar 13Carcinoma, Hepatocellular 11Carcinoma, Renal Cell 10Glioma 8Astrocytoma 8Salivary Gland Neoplasms 7Gallbladder Neoplasms 7Esophageal Neoplasms 7Carcinoma, Ovarian Epithelial 7Prostatic Neoplasms 6Ovarian Neoplasms 6Oligodendroglioma 6Fallopian Tube Neoplasms 6Carcinoma, Squamous Cell 6

Interventions

Carboplatin 8Paclitaxel 7Gemcitabine 7Irinotecan 6Radiotherapy 4Oxaliplatin 4Capecitabine 4Leucovorin 3Fluorouracil 3Filgrastim 3Erlotinib Hydrochloride 3Cisplatin 3Bevacizumab 3etoposide phosphate 2Trastuzumab 2Surveys and Questionnaires 2Peripheral Blood Stem Cell Transplantation 2Etoposide 2Amifostine 2Albumin-Bound Paclitaxel 2tipifarnib 1tegafur-gimeracil-oteracil 1sintilimab 1pertuzumab 1pemigatinib 1pembrolizumab 1olaparib 1ivosidenib 1ipatasertib 1erythromycin propionate-N-acetylcysteinate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neoplasms, Unknown Primary × Erlotinib Hydrochloride × Clear all
NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00360360 2013-12-04

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
60 enrolled 6 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00193622 2010-09-17

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡